CN104714025A - NT-proBNP检测试剂盒及检测方法 - Google Patents
NT-proBNP检测试剂盒及检测方法 Download PDFInfo
- Publication number
- CN104714025A CN104714025A CN201410704382.6A CN201410704382A CN104714025A CN 104714025 A CN104714025 A CN 104714025A CN 201410704382 A CN201410704382 A CN 201410704382A CN 104714025 A CN104714025 A CN 104714025A
- Authority
- CN
- China
- Prior art keywords
- probnp
- monoclonal antibody
- rare
- earth fluorescent
- pad
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 54
- 102400001263 NT-proBNP Human genes 0.000 title claims abstract 25
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 title claims abstract 25
- 229910052761 rare earth metal Inorganic materials 0.000 claims abstract description 54
- 150000002910 rare earth metals Chemical class 0.000 claims abstract description 50
- 238000012360 testing method Methods 0.000 claims abstract description 44
- 239000000020 Nitrocellulose Substances 0.000 claims abstract description 13
- 229920001220 nitrocellulos Polymers 0.000 claims abstract description 13
- 229910052747 lanthanoid Inorganic materials 0.000 claims abstract description 9
- 238000006243 chemical reaction Methods 0.000 claims abstract description 7
- 230000005284 excitation Effects 0.000 claims abstract description 4
- 230000005283 ground state Effects 0.000 claims abstract description 4
- -1 rare earth lanthanide Chemical class 0.000 claims abstract description 4
- 239000012530 fluid Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 13
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 239000007853 buffer solution Substances 0.000 claims description 12
- 238000004587 chromatography analysis Methods 0.000 claims description 12
- 239000003365 glass fiber Substances 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 12
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 11
- 238000002474 experimental method Methods 0.000 claims description 11
- 238000013016 damping Methods 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 7
- 238000005516 engineering process Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 206010003445 Ascites Diseases 0.000 claims description 5
- 230000000274 adsorptive effect Effects 0.000 claims description 5
- 150000002602 lanthanoids Chemical class 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000012898 sample dilution Substances 0.000 claims description 5
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 241000283707 Capra Species 0.000 claims description 3
- 229920001503 Glucan Polymers 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 3
- 230000003139 buffering effect Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 3
- 239000012279 sodium borohydride Substances 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 abstract description 11
- 239000004005 microsphere Substances 0.000 abstract description 6
- 230000035945 sensitivity Effects 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 4
- 238000003317 immunochromatography Methods 0.000 abstract description 3
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 13
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 12
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 9
- 206010019280 Heart failures Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 229910052691 Erbium Inorganic materials 0.000 description 2
- 229910052693 Europium Inorganic materials 0.000 description 2
- 229910052779 Neodymium Inorganic materials 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229910052772 Samarium Inorganic materials 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 2
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 108010079058 casein hydrolysate Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000011984 electrochemiluminescence immunoassay Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229960001267 nesiritide Drugs 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410704382.6A CN104714025B (zh) | 2014-11-28 | 2014-11-28 | NT‑proBNP检测试剂盒及检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410704382.6A CN104714025B (zh) | 2014-11-28 | 2014-11-28 | NT‑proBNP检测试剂盒及检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104714025A true CN104714025A (zh) | 2015-06-17 |
CN104714025B CN104714025B (zh) | 2017-05-17 |
Family
ID=53413533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410704382.6A Active CN104714025B (zh) | 2014-11-28 | 2014-11-28 | NT‑proBNP检测试剂盒及检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104714025B (zh) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105092832A (zh) * | 2015-08-28 | 2015-11-25 | 宁波瑞源生物科技有限公司 | 一种NT-proBNP荧光免疫试剂及其制备方法 |
CN105606825A (zh) * | 2016-02-01 | 2016-05-25 | 杭州惟新生物技术有限公司 | 一种胃泌素释放肽前体荧光免疫层析检测试剂盒 |
CN105717303A (zh) * | 2016-01-29 | 2016-06-29 | 山东康力医疗器械科技有限公司 | 一种用荧光免疫层析法检测磷酯酰肌醇蛋白聚糖3的方法及其试剂盒 |
CN106771168A (zh) * | 2016-12-30 | 2017-05-31 | 武汉纽康度生物科技股份有限公司 | 荧光免疫层析检测卡及其制备方法和应用 |
CN106872716A (zh) * | 2017-03-16 | 2017-06-20 | 威海纽普生物技术有限公司 | 血清淀粉样蛋白a和降钙素原二合一测定试剂盒及制法 |
CN106959371A (zh) * | 2017-03-16 | 2017-07-18 | 威海纽普生物技术有限公司 | 心肌肌钙蛋白i和n‑端脑利钠肽前体二合一测定试剂盒及制法 |
CN106959372A (zh) * | 2017-03-16 | 2017-07-18 | 威海纽普生物技术有限公司 | 血清淀粉样蛋白a和c‑反应蛋白二合一测定试剂盒及制法 |
CN106980020A (zh) * | 2017-03-16 | 2017-07-25 | 威海纽普生物技术有限公司 | 降钙素原和c‑反应蛋白二合一测定试剂盒及制法 |
CN106990254A (zh) * | 2016-12-15 | 2017-07-28 | 威海纽普生物技术有限公司 | 25‑羟基维生素d3测定试剂盒及制作方法 |
CN107044972A (zh) * | 2017-05-25 | 2017-08-15 | 沈阳优宁生物科技有限公司 | 一种微流控芯片荧光免疫快速检测试剂盒及其制备和检测方法 |
CN107607711A (zh) * | 2017-09-19 | 2018-01-19 | 威海纽普生物技术有限公司 | 铁蛋白检测试剂盒及其制备方法 |
CN107664700A (zh) * | 2017-09-19 | 2018-02-06 | 威海纽普生物技术有限公司 | 心肌肌钙蛋白i及肌酸激酶同工酶及肌红蛋白三合一检测试剂盒及其制备方法 |
CN107703110A (zh) * | 2017-09-19 | 2018-02-16 | 威海纽普生物技术有限公司 | 胃泌素17检测试剂盒及其制备方法 |
CN107703315A (zh) * | 2017-09-19 | 2018-02-16 | 威海纽普生物技术有限公司 | 叶酸检测试剂盒及其制备方法 |
CN107748264A (zh) * | 2017-09-19 | 2018-03-02 | 威海纽普生物技术有限公司 | 环瓜氨酸肽抗体和类风湿因子检测试剂盒及其制备方法 |
CN107907694A (zh) * | 2017-09-19 | 2018-04-13 | 威海纽普生物技术有限公司 | 抗穆勒氏管激素检测试剂盒及其制备方法 |
CN107907676A (zh) * | 2017-10-30 | 2018-04-13 | 威海纽普生物技术有限公司 | 阿尔茨海默相关神经丝蛋白检测试剂盒及其制备方法 |
CN107942066A (zh) * | 2017-10-30 | 2018-04-20 | 威海纽普生物技术有限公司 | 白介素‑6检测试剂盒及其制备方法 |
CN112608385A (zh) * | 2020-12-18 | 2021-04-06 | 杭州贤至生物科技有限公司 | 一种犬脑钠肽(bnp)单克隆抗体的制备 |
CN112710855A (zh) * | 2020-12-15 | 2021-04-27 | 深圳天辰医疗科技有限公司 | Bnp检测试剂盒和bnp的检测方法 |
CN112964885A (zh) * | 2021-02-20 | 2021-06-15 | 广东菲鹏生物有限公司 | 一种氨基末端脑尿钠肽检测方法和试剂盒 |
CN113474657A (zh) * | 2019-02-21 | 2021-10-01 | 丁勤学 | 使用微粒去除非特异性结合信号的方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0158973A2 (en) * | 1984-04-12 | 1985-10-23 | The General Hospital Corporation | Multisite immunometric assay |
US20080070234A1 (en) * | 2006-09-11 | 2008-03-20 | Roche Diagnostics Operations, Inc. | Measuring Range Extension of Chromatographic Rapid Tests |
CN101627310A (zh) * | 2007-03-07 | 2010-01-13 | 生物医学医药产品有限责任两合公司 | 测定NT-proBNP的方法 |
CN102608335A (zh) * | 2012-04-19 | 2012-07-25 | 协和生物制药(天津)有限公司 | NT-proBNP时间分辨荧光免疫分析试剂盒的制备方法 |
CN103172941A (zh) * | 2011-12-26 | 2013-06-26 | 苏州新波生物技术有限公司 | 聚苯乙烯荧光纳米颗粒及其制备和应用 |
CN103197074A (zh) * | 2013-04-22 | 2013-07-10 | 北京润博福得生物科技发展有限公司 | 基于近红外荧光纳米微球标记物的免疫层析定量检测试剂 |
CN103901201A (zh) * | 2014-03-28 | 2014-07-02 | 中国检验检疫科学研究院 | 头孢氨苄残留荧光免疫层析检测试纸条及其制备 |
-
2014
- 2014-11-28 CN CN201410704382.6A patent/CN104714025B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0158973A2 (en) * | 1984-04-12 | 1985-10-23 | The General Hospital Corporation | Multisite immunometric assay |
US20080070234A1 (en) * | 2006-09-11 | 2008-03-20 | Roche Diagnostics Operations, Inc. | Measuring Range Extension of Chromatographic Rapid Tests |
CN101627310A (zh) * | 2007-03-07 | 2010-01-13 | 生物医学医药产品有限责任两合公司 | 测定NT-proBNP的方法 |
CN103172941A (zh) * | 2011-12-26 | 2013-06-26 | 苏州新波生物技术有限公司 | 聚苯乙烯荧光纳米颗粒及其制备和应用 |
CN102608335A (zh) * | 2012-04-19 | 2012-07-25 | 协和生物制药(天津)有限公司 | NT-proBNP时间分辨荧光免疫分析试剂盒的制备方法 |
CN103197074A (zh) * | 2013-04-22 | 2013-07-10 | 北京润博福得生物科技发展有限公司 | 基于近红外荧光纳米微球标记物的免疫层析定量检测试剂 |
CN103901201A (zh) * | 2014-03-28 | 2014-07-02 | 中国检验检疫科学研究院 | 头孢氨苄残留荧光免疫层析检测试纸条及其制备 |
Non-Patent Citations (4)
Title |
---|
GOETZEJP ET AL.: "impact of epitope specificity and precursor maturation in pro-B-type natriuretic peptide measurement", 《CLINICAL CHEMISTRY》 * |
impact of epitope specificity and precursor maturation in pro-B-type natriuretic peptide measurement;GoetzeJP ET AL.;《Clinical Chemistry》;20081130;第54卷(第11期);1780-1787 * |
徐秀宇等: "抗人脑钠肽前体氮端肽(NT-proBNP)单克隆抗体的制备及其性质鉴定", 《重庆市生物化学与分子生物学学术会议论文摘要汇编》 * |
抗人脑钠肽前体氮端肽(NT-proBNP)单克隆抗体的制备及其性质鉴定;徐秀宇等;《重庆市生物化学与分子生物学学术会议论文摘要汇编》;20091231;15 * |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105092832A (zh) * | 2015-08-28 | 2015-11-25 | 宁波瑞源生物科技有限公司 | 一种NT-proBNP荧光免疫试剂及其制备方法 |
CN105092832B (zh) * | 2015-08-28 | 2016-11-30 | 宁波瑞源生物科技有限公司 | 一种NT-proBNP荧光免疫试剂及其制备方法 |
CN105717303A (zh) * | 2016-01-29 | 2016-06-29 | 山东康力医疗器械科技有限公司 | 一种用荧光免疫层析法检测磷酯酰肌醇蛋白聚糖3的方法及其试剂盒 |
CN105606825A (zh) * | 2016-02-01 | 2016-05-25 | 杭州惟新生物技术有限公司 | 一种胃泌素释放肽前体荧光免疫层析检测试剂盒 |
CN106990254A (zh) * | 2016-12-15 | 2017-07-28 | 威海纽普生物技术有限公司 | 25‑羟基维生素d3测定试剂盒及制作方法 |
US20190219569A1 (en) * | 2016-12-30 | 2019-07-18 | Wuhan Newcando Biotechnology Co., Ltd. | Fluorescence immunochromatographic detection card and a preparation method therefor and use thereof |
US11959912B2 (en) * | 2016-12-30 | 2024-04-16 | Wuhan Newcando Biotechnology Co., Ltd. | Fluorescence immunochromatographic detection card and a preparation method therefor and use thereof |
CN106771168A (zh) * | 2016-12-30 | 2017-05-31 | 武汉纽康度生物科技股份有限公司 | 荧光免疫层析检测卡及其制备方法和应用 |
CN106872716A (zh) * | 2017-03-16 | 2017-06-20 | 威海纽普生物技术有限公司 | 血清淀粉样蛋白a和降钙素原二合一测定试剂盒及制法 |
CN106959371A (zh) * | 2017-03-16 | 2017-07-18 | 威海纽普生物技术有限公司 | 心肌肌钙蛋白i和n‑端脑利钠肽前体二合一测定试剂盒及制法 |
CN106959372A (zh) * | 2017-03-16 | 2017-07-18 | 威海纽普生物技术有限公司 | 血清淀粉样蛋白a和c‑反应蛋白二合一测定试剂盒及制法 |
CN106980020A (zh) * | 2017-03-16 | 2017-07-25 | 威海纽普生物技术有限公司 | 降钙素原和c‑反应蛋白二合一测定试剂盒及制法 |
CN107044972A (zh) * | 2017-05-25 | 2017-08-15 | 沈阳优宁生物科技有限公司 | 一种微流控芯片荧光免疫快速检测试剂盒及其制备和检测方法 |
CN107664700A (zh) * | 2017-09-19 | 2018-02-06 | 威海纽普生物技术有限公司 | 心肌肌钙蛋白i及肌酸激酶同工酶及肌红蛋白三合一检测试剂盒及其制备方法 |
CN107703315A (zh) * | 2017-09-19 | 2018-02-16 | 威海纽普生物技术有限公司 | 叶酸检测试剂盒及其制备方法 |
CN107748264A (zh) * | 2017-09-19 | 2018-03-02 | 威海纽普生物技术有限公司 | 环瓜氨酸肽抗体和类风湿因子检测试剂盒及其制备方法 |
CN107907694A (zh) * | 2017-09-19 | 2018-04-13 | 威海纽普生物技术有限公司 | 抗穆勒氏管激素检测试剂盒及其制备方法 |
CN107703110A (zh) * | 2017-09-19 | 2018-02-16 | 威海纽普生物技术有限公司 | 胃泌素17检测试剂盒及其制备方法 |
CN107607711A (zh) * | 2017-09-19 | 2018-01-19 | 威海纽普生物技术有限公司 | 铁蛋白检测试剂盒及其制备方法 |
CN107907676A (zh) * | 2017-10-30 | 2018-04-13 | 威海纽普生物技术有限公司 | 阿尔茨海默相关神经丝蛋白检测试剂盒及其制备方法 |
CN107942066A (zh) * | 2017-10-30 | 2018-04-20 | 威海纽普生物技术有限公司 | 白介素‑6检测试剂盒及其制备方法 |
CN113474657A (zh) * | 2019-02-21 | 2021-10-01 | 丁勤学 | 使用微粒去除非特异性结合信号的方法 |
CN112710855A (zh) * | 2020-12-15 | 2021-04-27 | 深圳天辰医疗科技有限公司 | Bnp检测试剂盒和bnp的检测方法 |
CN112608385B (zh) * | 2020-12-18 | 2022-05-20 | 杭州贤至生物科技有限公司 | 一种犬脑钠肽(bnp)单克隆抗体的制备 |
CN112608385A (zh) * | 2020-12-18 | 2021-04-06 | 杭州贤至生物科技有限公司 | 一种犬脑钠肽(bnp)单克隆抗体的制备 |
CN112964885A (zh) * | 2021-02-20 | 2021-06-15 | 广东菲鹏生物有限公司 | 一种氨基末端脑尿钠肽检测方法和试剂盒 |
CN112964885B (zh) * | 2021-02-20 | 2022-11-11 | 广东菲鹏生物有限公司 | 一种氨基末端脑尿钠肽检测方法和试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
CN104714025B (zh) | 2017-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104714025A (zh) | NT-proBNP检测试剂盒及检测方法 | |
CN104714033A (zh) | 降钙素原检测试剂盒及检测方法 | |
CN104730245B (zh) | D二聚体检测试剂盒及检测方法 | |
CN104730251B (zh) | 肌钙蛋白i检测试剂盒及检测方法 | |
CN104714015B (zh) | 心型脂肪酸结合蛋白检测试剂盒及检测方法 | |
CN108254563B (zh) | 检测cTnI的时间分辨荧光免疫层析试纸条、试剂盒及其制备方法 | |
CN106706926A (zh) | 血清淀粉样蛋白a测定试剂盒及制作方法 | |
CN102662055B (zh) | 一种快速定量检测肌钙蛋白i的免疫荧光试纸条组件、及其制成的检测卡组件和制备方法 | |
CN106841631A (zh) | 心肌肌钙蛋白i/n‑端脑利钠肽前体/d二聚体三合一测定试剂盒及制法 | |
CN107664700A (zh) | 心肌肌钙蛋白i及肌酸激酶同工酶及肌红蛋白三合一检测试剂盒及其制备方法 | |
CN102087293A (zh) | 一种全程定量检测肌钙蛋白i的免疫层析试纸条及其制备方法 | |
CN102692504A (zh) | D-二聚体荧光免疫定量测定试纸条及其制备方法 | |
CN107703110A (zh) | 胃泌素17检测试剂盒及其制备方法 | |
CN106959372A (zh) | 血清淀粉样蛋白a和c‑反应蛋白二合一测定试剂盒及制法 | |
CN105717303A (zh) | 一种用荧光免疫层析法检测磷酯酰肌醇蛋白聚糖3的方法及其试剂盒 | |
CN106771239A (zh) | 血清淀粉样蛋白a/降钙素原/c‑反应蛋白三合一测定试剂盒及制法 | |
CN102608335A (zh) | NT-proBNP时间分辨荧光免疫分析试剂盒的制备方法 | |
CN106771128A (zh) | 甲状旁腺激素测定试剂盒及制作方法 | |
CN107907676A (zh) | 阿尔茨海默相关神经丝蛋白检测试剂盒及其制备方法 | |
CN107918022A (zh) | 一种cTnI检测试剂盒及其使用方法 | |
CN108931636A (zh) | 测定st2的荧光免疫层析检测试剂盒及其制备方法 | |
CN106990254A (zh) | 25‑羟基维生素d3测定试剂盒及制作方法 | |
CN106872716A (zh) | 血清淀粉样蛋白a和降钙素原二合一测定试剂盒及制法 | |
CN107942066A (zh) | 白介素‑6检测试剂盒及其制备方法 | |
CN105954509A (zh) | 肾素化学发光免疫检测试剂盒及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Teng Zhitao Inventor after: Yu Hongxiang Inventor after: Chen Pingping Inventor before: Wang Youzhi Inventor before: Wang Penghao Inventor before: Cai Rong |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: NT proBNP detection kit and detection method Effective date of registration: 20230628 Granted publication date: 20170517 Pledgee: Weihai Branch of Bank of Communications Co.,Ltd. Pledgor: WEIHAI NEOPROBIO. CO.,LTD. Registration number: Y2023980046073 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20170517 Pledgee: Weihai Branch of Bank of Communications Co.,Ltd. Pledgor: WEIHAI NEOPROBIO. CO.,LTD. Registration number: Y2023980046073 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |